T A Buchholz

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells
    Bisrat G Debeb
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mol Cancer 9:180. 2010
  2. ncbi Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
  3. ncbi 1st annual oncology update: advances and controversies. Steamboat Springs, Colorado, USA, 13-17 February 2001
    T A Buchholz
    Department of Radiation Oncology, Box 97, 1515 Holcombe Blvd, University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
    Expert Rev Anticancer Ther 1:6-8. 2001
  4. ncbi Preparing for the future of radiation oncology
    Thomas A Buchholz
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Coll Radiol 4:560-2. 2007
  5. ncbi Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1155-60. 2006
  6. ncbi Molecular biology and genetics of breast cancer development: a clinical perspective
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 12:285-95. 2002
  7. ncbi Controversies regarding the use of radiation after mastectomy in breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 7:539-46. 2002
  8. ncbi The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:361-9. 2006
  9. ncbi The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
  10. ncbi Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005

Detail Information

Publications97

  1. ncbi Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells
    Bisrat G Debeb
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mol Cancer 9:180. 2010
    ..Herein we fully characterize cancer stem cell-like features in 293T human embryonic kidney cells...
  2. ncbi Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
    ..We investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment...
  3. ncbi 1st annual oncology update: advances and controversies. Steamboat Springs, Colorado, USA, 13-17 February 2001
    T A Buchholz
    Department of Radiation Oncology, Box 97, 1515 Holcombe Blvd, University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
    Expert Rev Anticancer Ther 1:6-8. 2001
    ..In general, the conference was able to provide an excellent multidisciplinary overview of a wide-variety of oncology topics...
  4. ncbi Preparing for the future of radiation oncology
    Thomas A Buchholz
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Coll Radiol 4:560-2. 2007
    ..It is very important that radiation oncology develop a more comprehensive strategy to address this need. Doing so will ensure the preservation and growth of the profession...
  5. ncbi Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1155-60. 2006
    ....
  6. ncbi Molecular biology and genetics of breast cancer development: a clinical perspective
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 12:285-95. 2002
    ..By participating in the study of breast cancer development at the molecular as well as the histopathological level, oncologists can help develop novel prevention, diagnostic, and therapeutic approaches for the future...
  7. ncbi Controversies regarding the use of radiation after mastectomy in breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 7:539-46. 2002
    ..In this article we discuss these controversies, review the data that are relevant, and provide our institutional approaches to these issues...
  8. ncbi The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:361-9. 2006
    ..We investigated rates of radiation use after breast conservation therapy (BCT) for patients treated for ductal carcinoma-in-situ (DCIS) or invasive breast cancer at National Comprehensive Cancer Network (NCCN) centers...
  9. ncbi The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
    ....
  10. ncbi Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005
    ..To the authors' knowledge there are few data that correlate the expression of the epidermal growth factor receptor (EGFR) with the outcome of patients who have breast carcinoma and are treated with anthracycline chemotherapy...
  11. ncbi Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Surg Clin North Am 83:911-30, x. 2003
    ..For these patients, radiation treatment fields must be specifically designed to include the appropriate nodal regions within the target treatment volumes...
  12. ncbi Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1150-60. 2003
    ..Over the past decade, it has become increasingly more common to deliver chemotherapy first, but this has raised new questions within all disciplines of cancer management...
  13. ncbi Is partial breast irradiation a step forward or backward?
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 15:69-75. 2005
    ..This would be a big step backward in the role of radiation therapy in breast cancer treatment...
  14. ncbi Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:1337-42. 2004
    ..We retrospectively studied whether Her2/neu-positive disease was associated with locoregional recurrence (LRR) after postmastectomy radiotherapy (RT) for breast cancer...
  15. ncbi Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer
    Jing Li
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1675-83. 2011
    ..However, these findings have not been confirmed for inflammatory breast cancer (IBC), which has different biological features than non-IBC...
  16. ncbi Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:880-8. 2002
    ..To compare the pathologic factors associated with postmastectomy locoregional recurrence (LRR) in breast cancer patients not receiving radiation who were treated with neoadjuvant chemotherapy (NEO) vs. adjuvant chemotherapy (ADJ)...
  17. ncbi A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:1345-51. 2004
    ....
  18. ncbi Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy
    T A Buchholz
    Departments of Radiation Oncology, Biomathematics, Breast Medical Oncology, and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:2240-6. 2001
    ..To determine the impact of tamoxifen and chemotherapy on local control for breast cancer patients treated with breast-conservation therapy...
  19. ncbi Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 20:17-23. 2002
    ..To define clinical and pathologic predictors of local-regional recurrence (LRR) for patients treated with neoadjuvant chemotherapy and mastectomy without radiation...
  20. ncbi Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcolmbe Blvd, Unit 1202, Houston, TX 77030, USA
    J Clin Oncol 26:791-7. 2008
    ..To review the state of the science with respect to diagnostic imaging and locoregional therapy for patients with breast cancer receiving preoperative chemotherapy...
  21. ncbi Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:4691-9. 2004
    ..Radiation should be considered for these patients regardless of their response to initial chemotherapy...
  22. ncbi Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy
    T A Buchholz
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
    Cancer J 7:413-20. 2001
    ..However, more active systemic and local therapies are needed for patients with estrogen receptor-negative disease and positive lymph nodes and for those with clinical evidence of progressive disease during neoadjuvant chemotherapy...
  23. ncbi Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience
    G Vlastos
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:1092-100. 2001
    ..This treatment should be considered as the standard of care for elderly patients without severe comorbid disease...
  24. ncbi The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy
    A Katz
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 50:735-42. 2001
    ..These factors predict for high LRR rates regardless of the number of involved axillary nodes...
  25. ncbi Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant
    T A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 46:337-43. 2000
    ..To determine local-regional failure rates in breast cancer patients treated with surgery and high-dose chemotherapy with stem cell transplant and to relate local-regional failure to the use and timing of radiation treatment...
  26. ncbi Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma
    H M Kuerer
    Department of Surgical Oncology, Box 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 182:601-8. 2001
    ..Resection of the tumor bed remains necessary in women deemed to have a complete clinical response to ensure low rates of recurrence...
  27. ncbi Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation
    A Katz
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 50:397-403. 2001
    ..Patients with 20% or greater involved nodes and those with less than 20% nodes and tumors of 5.0 cm or greater are at significant risk of LRR and should be considered for postoperative irradiation...
  28. ncbi Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:490-8. 2004
    ..VR must be considered when selecting patients for balloon catheter-based APBI, because a minority of patients will have a lumpectomy cavity that exceeds the size limit of the current balloon device...
  29. ncbi Tumor suppressor genes and breast cancer
    T A Buchholz
    Department of Radiation Oncology, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Radiat Oncol Investig 7:55-65. 1999
    ....
  30. ncbi Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:336-44. 2003
    ..CONCLUSIONS: Postmastectomy radiation decreases LRR for patients with breast cancer, including those with Stage II breast cancer and one to three positive lymph nodes...
  31. ncbi Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 62:351-7. 2005
    ..Patients with three or more of these factors may benefit from research protocols investigating alternative treatment strategies...
  32. ncbi Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1022-7. 2008
    ..For patients with Stage II breast cancer with one to three positive lymph nodes, controversy exists about whether radiation as a component of treatment provides a survival benefit...
  33. ncbi Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study
    Grace L Smith
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Head Neck 31:1031-8. 2009
    ..In patients with head and neck cancer, radiation treatment (RT) is a risk factor for hypothyroidism. However, the specific magnitude of risk after RT in older patients is not known...
  34. ncbi Identifying factors that impact survival among women with inflammatory breast cancer
    S Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Ann Oncol 23:870-5. 2012
    ..The objective of this retrospective study was to determine factors impacting survival among women with inflammatory breast cancer (IBC)...
  35. ncbi Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
    C Mazouni
    Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Ann Oncol 18:874-80. 2007
    ....
  36. ncbi Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:220-6. 2009
    ..The goal of this study was to describe the effect of race on pathologic complete response (pCR) rates and survival outcomes in women with triple receptor-negative (TN) breast cancers...
  37. ncbi Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ
    Tina W F Yen
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:942-9. 2004
    ..The current findings have implications for current trials evaluating aromatase inhibitors and other chemopreventive agents for this disease...
  38. ncbi Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 8:461-8. 2002
    ..A remarkable diversity in transcriptional response was observed for individual cases. Further data are needed to determine whether gene profiling can predict response to chemotherapy...
  39. ncbi Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation
    P J Schlembach
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 51:671-8. 2001
    ....
  40. ncbi Inflammatory breast cancer: current concepts in local management
    Ian J Bristol
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Breast Dis 22:75-83. 2005
    ..We analyze the relevant literature pertaining to those local treatment options, review treatment techniques, and provide evidence-based treatment recommendations fro practicing oncologists...
  41. ncbi Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy
    Nadeem Q Mirza
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 9:256-65. 2002
    ..Disease-specific survival among patients with LRR was similar to that among patients with no recurrence. CONCLUSIONS: Multidisciplinary treatment strategies should be used to accomplish durable locoregional control after BCT...
  42. ncbi Improving local control with breast-conserving therapy: a 27-year single-institution experience
    Neslihan Cabioglu
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:20-9. 2005
    ..The current low incidence of IBTR with multidisciplinary management of breast carcinoma may result in more patients choosing BCT over mastectomy...
  43. ncbi Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
    Ian J Bristol
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:474-84. 2008
    ....
  44. ncbi Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy
    Amit K Garg
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:1478-83. 2007
    ..The objective of this study was to assess the benefits of PMRT in patients <35 years old treated with doxorubicin-based neoadjuvant chemotherapy for Stage II-III breast cancer...
  45. ncbi T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy
    Amit K Garg
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:138-45. 2004
    ..For most patients with clinical T1 or T2 disease and one to three positive lymph nodes, the 5-year risk for LRR was low, and the routine inclusion of postmastectomy radiotherapy does not appear to be justified...
  46. ncbi High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy
    N T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 37:929-35. 2006
    ..Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable. A randomized study is warranted in this patient population...
  47. ncbi Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:352-7. 2006
    ..If these findings are confirmed in larger randomized studies, the prognostic index may be useful in helping to select the type of surgical treatment for patients treated with neoadjuvant chemotherapy, surgery, and radiation...
  48. ncbi Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Int J Radiat Oncol Biol Phys 57:327-35. 2003
    ..The rate of second non-breast cancer malignancy was increased among patients treated with >10 cycles of cyclophosphamide-containing chemotherapy...
  49. ncbi Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer
    Jeffrey M Albert
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 77:1296-302. 2010
    ....
  50. ncbi Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry
    Anees Chagpar
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:1581-6. 2005
    ..543 and P = 0.540, respectively). CONCLUSIONS: Although the finding of SLN micrometastases by IHC may change management in > 12% of patients, preliminary results suggested that such micrometastases do not affect outcomes significantly...
  51. ncbi Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients
    Tse-Kuan Yu
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 96:1676-81. 2004
    ....
  52. ncbi Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields
    Karen H Shahar
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:1074-9. 2004
    ..The remaining patients have a greater risk of having four or more positive lymph nodes, and, therefore, the high axilla/supraclavicular fossa should also be included in the radiation fields...
  53. ncbi Effects of variable placement of superior tangential/supraclavicular match line on dosimetric coverage of level III axilla/axillary apex in patients treated with breast and supraclavicular radiotherapy
    Amit K Garg
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 73:370-4. 2009
    ....
  54. ncbi The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy
    Sabin B Motwani
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:76-82. 2006
    ..For patients with locally advanced breast cancer, the potential for compromised PMRT planning should be considered when deciding between immediate and delayed reconstruction...
  55. ncbi Risk of hypothyroidism in older breast cancer patients treated with radiation
    Grace L Smith
    Department of Breast Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:1371-9. 2008
    ..The authors assessed risk of hypothyroidism in breast cancer patients who were receiving RT to a supraclavicular field, which typically includes a portion of thyroid...
  56. ncbi Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma
    Jianzhou Wang
    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:3107-14. 2002
    ....
  57. ncbi Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach
    Beth M Beadle
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 73:734-44. 2009
    ..The goal of this study is to determine the impact of locoregional treatment strategy, breast-conserving therapy (BCT), mastectomy alone (M), or mastectomy with adjuvant radiation (MXRT), on LRR for patients 35 years or younger...
  58. ncbi Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience
    Allen M Chen
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2303-12. 2004
    ..Advanced nodal involvement at diagnosis, residual tumor larger than 2 cm, multifocal residual disease, and lymphovascular space invasion predict higher rates of LRR and IBTR...
  59. ncbi Breast cancer regional radiation fields for supraclavicular and axillary lymph node treatment: is a posterior axillary boost field technique optimal?
    Xiaochun Wang
    Department of Radiation Physics, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 74:86-91. 2009
    ....
  60. ncbi Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction
    Anees Chagpar
    Department of Surgical Oncology, Box 444, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 187:164-9. 2004
    ..Collaboration with a plastic surgery team may be beneficial in the surgical management of these patients...
  61. ncbi Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005
    ..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel...
  62. ncbi Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy
    Jeannie Shen
    Department of Surgical Oncology, Unit 444, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Ann Surg Oncol 11:854-60. 2004
    ..These patients have favorable rates of long-term local control and survival. Mastectomy is not mandatory for all patients with breast cancer who present with skin involvement...
  63. ncbi Population-based analysis of occult primary breast cancer with axillary lymph node metastasis
    Gary V Walker
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4000-6. 2010
    ..Population-based multi-institutional data supporting this approach are lacking...
  64. ncbi A custom three-dimensional electron bolus technique for optimization of postmastectomy irradiation
    G H Perkins
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 51:1142-51. 2001
    ..The radiation dose distribution is highly conformal, dose heterogeneity is reduced compared to standard techniques in certain suboptimal settings, and excellent immediate outcome is obtained...
  65. ncbi Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States
    Grace L Smith
    Department of Radiation Oncology, The Section of Health Services Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Am Coll Surg 209:425-433.e2. 2009
    ..But earlier studies report low BCS use rates of 12% to 43% nationally, especially in older patients. We sought to determine current patterns and predictors of BCS use...
  66. ncbi Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study
    X Allen Li
    Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Int J Radiat Oncol Biol Phys 73:944-51. 2009
    ....
  67. ncbi Treatment optimization using computed tomography-delineated targets should be used for supraclavicular irradiation for breast cancer
    Raweewan Liengsawangwong
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:711-5. 2007
    ....
  68. ncbi Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy
    Sean E McGuire
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:1004-9. 2007
    ..The aim of this study was to investigate the role of postmastectomy radiation therapy in women with breast cancer who achieved a pathologic complete response (pCR) to neoadjuvant chemotherapy...
  69. ncbi The biologic rationale for and emerging role of accelerated partial breast irradiation for breast cancer
    Timothy M Pawlik
    Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 199:479-92. 2004
  70. ncbi Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer
    Eugene Huang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:1225-33. 2002
    ..Alternative therapeutic strategies such as novel systemic agents, use of planned myocutaneous repair for closure, or radiation combined with radiosensitizing agents, should be considered in this class of patients...
  71. ncbi Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
    Jacqueline S Jeruss
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 26:246-52. 2008
    ..We hypothesized that by using clinical and pathologic staging parameters, in conjunction with biologic tumor markers, a novel means of determining prognosis for patients treated with neoadjuvant chemotherapy could be facilitated...
  72. ncbi Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response
    Darren W Davis
    Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:955-60. 2003
    ..CONCLUSIONS: If the results can be validated in a larger patient cohort, the method could be used to "tailor" therapy to optimize benefit in a patient-specific fashion...
  73. ncbi Incidence of and survival following brain metastases among women with inflammatory breast cancer
    S Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Oncol 21:2348-55. 2010
    ..The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC)...
  74. ncbi Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer
    M Chavez-MacGregor
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Ann Oncol 22:2394-402. 2011
    ..The purpose of this study is to evaluate the risk factors and the prevalence of thromboembolic events (TEEs) in breast cancer patients...
  75. ncbi Verification of tangential breast treatment dose calculations in a commercial 3D treatment planning system
    C T Baird
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Appl Clin Med Phys 2:73-84. 2001
    ..These results indicated that the treatment planning system calculates doses at the midplane with clinically acceptable accuracy in conditions simulating tangential breast treatment...
  76. ncbi Chest wall recurrence after mastectomy does not always portend a dismal outcome
    Anees Chagpar
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:628-34. 2003
    ..0001). CONCLUSIONS: Patients with CWR are a heterogeneous population. Patients with initial node-negative disease who develop CWR after 24 months have an optimistic prognosis, especially if they are treated with radiation...
  77. ncbi Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation
    Michael P Greenbaum
    The Methodist Hospital, Houston, TX, USA
    Radiother Oncol 95:312-6. 2010
    ..To determine the rate of locoregional recurrence (LRR) associated with modern tri-modality therapy...
  78. ncbi Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence
    Jeannie Shen
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 104:479-90. 2005
    ..Determinants of prognosis after IBTR should be taken into account when evaluating the need for further systemic therapy and designing risk-stratified clinical trials...
  79. ncbi Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study
    Marilyn Stovall
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:1021-30. 2008
    ..To quantify the risk of second primary breast cancer in the contralateral breast (CB) after radiotherapy (RT) for first breast cancer...
  80. ncbi Nuclear factor-kappa B as a predictor of treatment response in breast cancer
    Amit K Garg
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA
    Curr Opin Oncol 15:405-11. 2003
    ..Gaining further insights into molecular factors such as NF-kappa B as biomarkers for treatment response may help clinicians predict treatment outcome and lead to the development of targeted therapeutics...
  81. ncbi Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy
    Grace L Smith
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:5119-25. 2008
    ..Cerebrovascular disease is common in head and neck cancer patients, but it is unknown whether radiotherapy increases the cerebrovascular disease risk in this population...
  82. ncbi Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger
    Scott R Floyd
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 66:358-64. 2006
    ..LVI was significantly associated with LRF in our series, indicating that patients with this risk factor require careful consideration with regard to further local therapy...
  83. ncbi Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis
    Eugene H Huang
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:490-6. 2007
    ..To evaluate the locoregional efficacy of multimodality treatment for breast cancer patients who present with ipsilateral supraclavicular (SCV) disease without systemic metastases...
  84. ncbi Role for intraoperative margin assessment in patients undergoing breast-conserving surgery
    Neslihan Cabioglu
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, 77030, USA
    Ann Surg Oncol 14:1458-71. 2007
    ..We investigated whether intraoperative margin assessment aids in obtaining negative margins, and to evaluate the local control thus achieved...
  85. ncbi Accelerated partial breast irradiation
    Gregory M Chronowski
    Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Curr Probl Cancer 31:7-25. 2007
  86. ncbi Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort
    Grace L Smith
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Int J Radiat Oncol Biol Phys 74:482-9. 2009
    ..Optimal management of elderly patients with nonmetastatic esophageal cancer is unclear. Outcomes data after locoregional treatment are lacking for this group...
  87. ncbi Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment
    H D Thames
    Departments of Biomathematics and Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2649-58. 1999
    ..The sequencing of treatment for early breast cancer is controversial. The purpose of this study was to quantify the risk of delaying surgery, using estimates of the frequency of first metastases from breast primary tumors...
  88. ncbi Isoseparation curves: a mechanism for optimizing off-axis dose homogeneity of intact breast irradiation
    T A Buchholz
    Department of Radiation Oncology, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Radiat Oncol Investig 6:191-8. 1998
    ..The greatest improvements are in the inferior quadrants of the intact breast. The improved dose homogeneity may have clinical relevance in the treatment of patients with large breast sizes...
  89. ncbi Biphasic metaplastic sarcomatoid carcinoma of the breast
    B T Hennessy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 17:605-13. 2006
    ..D. Anderson Cancer Center (MDACC) with 213 MSC and 98 carcinosarcoma patients identified through the Surveillance, Epidemiology and End-Results (SEER) database to describe clinical and pathologic characteristics...
  90. ncbi Now and later? The sticky question of lymph node management in patients receiving preoperative chemotherapy
    Kelly K Hunt
    Ann Surg Oncol 12:683-5. 2005
  91. ncbi Long-term complications associated with breast-conservation surgery and radiotherapy
    Funda Meric
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Ann Surg Oncol 9:543-9. 2002
    ..Breast-conservation surgery and radiotherapy is associated with grade 2 or greater complications in only 9.9% of patients. Nearly half of these complications are attributable to axillary dissection...
  92. ncbi Effectiveness of radiation therapy in older women with ductal carcinoma in situ
    Benjamin D Smith
    Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA
    J Natl Cancer Inst 98:1302-10. 2006
    ..In a cohort of older women with DCIS, we sought to determine whether radiation therapy was associated with a clinically significant benefit...
  93. ncbi Should intensity-modulated radiation therapy be the standard of care in the conservatively managed breast cancer patient?
    Bruce G Haffty
    J Clin Oncol 26:2072-4. 2008
  94. ncbi Immediate breast reconstruction after skin-sparing mastectomy for the treatment of advanced breast cancer: radiation oncology considerations
    Thomas A Buchholz
    Ann Surg Oncol 9:820-1. 2002
  95. ncbi Lung carcinoma development after radiotherapy for breast carcinoma
    Thomas A Buchholz
    Cancer 98:1331-3. 2003
  96. ncbi Optimizing locoregional control and survival for women with breast cancer: a review of current developments in postmastectomy radiotherapy
    Pauline T Truong
    British Columbia Cancer Agency, Vancouver Island Center, University of British Columbia, Victoria, BC, Canada
    Expert Rev Anticancer Ther 6:205-16. 2006
    ..They also summarize key issues related to the integration of PMRT with other treatment modalities...
  97. ncbi The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Colum
    Pauline T Truong
    Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Island Centre, British Columbia Cancer Agency, University of British Columbia, Victoria, BC, Canada
    Int J Radiat Oncol Biol Phys 68:59-65. 2007
    ....